Mice treated with the drug had much smaller dead-cell areas in their artery plaques—almost half as big—which might mean their plaques are less likely to break open.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Randomized Controlled Trial

Animal

2023

The study found that a new drug called MPE-298 made dangerous fatty buildups in the arteries of mice more stable and less likely to rupture — which is exactly what the claim says it does.

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Source Study

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Score: 12

DOI: 10.3389/fphar.2023.1204905

Similar Assertions

The drug didn’t lower the mice’s overall cholesterol, so its benefits must come from something else—like reducing inflammation or cell death in plaques.

86%

The drug lowered the levels of two proteins in the arteries that are known to break down plaque structure, which might help keep plaques from bursting.

82%

The drug didn’t affect blood sugar or fat levels in the blood, so its benefits aren’t due to improving how the body handles sugar or fat.

81%

The mice didn’t gain or lose weight or eat differently with the drug, so the benefits aren’t just because they were eating less or changing their metabolism.

81%

The drug lowered two key inflammation signals in the blood by nearly half, which may help calm down the body’s harmful immune response in the arteries.

80%